Bharat Biotech gets DCGI emergency use nod for Intranasal COVID vaccine
Union Minister of Health and Family Welfare Mansukh Mandaviya termed it a 'Big boost' to India's fight against Covid-19.
New Delhi: The Bharat Biotech on Tuesday got emergency use authorisation from the Drugs Controller General of India (DCGI) for the Intranasal Covid-19 vaccine.
"This step will further strengthen our collective fight against the pandemic. India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji's leadership," he added.
He also said that we will defeat Covid-19 with a science-driven approach.
"With the science-driven approach and Sabka Prayas, we will defeat COVID-19," he said.
Read also: COVID-19: Bharat Biotech intranasal vaccine found safe in booster trials
Bharat Biotech International Limited is an Indian multinational biotechnology company headquartered in Genome Valley, Turakapally, Hyderabad. The company was founded by Krishna Ella in 1996.
It is engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products.
Read also: Bharat Biotech expects DCGI nod for intranasal COVID vaccine this month
